

BALTIMORE DAVID  
Form 4  
November 13, 2018

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
BALTIMORE DAVID

2. Issuer Name and Ticker or Trading Symbol  
Regulus Therapeutics Inc. [RGLS]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/12/2018

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

SAN DIEGO, CA 92121

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(D)	Price
Common Stock	11/12/2018		A		40,339	A	<u>(1)</u>
					44,131	<u>(2)</u>	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: BALTIMORE DAVID - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (Right to Buy)	\$ 4.56	11/12/2018		D	10,625 (2)	(3) 01/01/2019	Common Stock	10,625 (2)
Stock Option (Right to Buy)	\$ 4.56	11/12/2018		D	1,875 (2)	(3) 01/01/2019	Common Stock	1,875 (2)
Stock Option (Right to Buy)	\$ 4.56	11/12/2018		D	625 (2)	(3) 12/01/2019	Common Stock	625 (2)
Stock Option (Right to Buy)	\$ 4.56	11/12/2018		D	1,458 (2)	(3) 12/01/2019	Common Stock	1,458 (2)
Stock Option (Right to Buy)	\$ 20.88	11/12/2018		D	625 (2)	(3) 01/02/2021	Common Stock	625 (2)
Stock Option (Right to Buy)	\$ 20.88	11/12/2018		D	1,458 (2)	(3) 01/02/2021	Common Stock	1,458 (2)
Stock Option (Right to Buy)	\$ 31.92	11/12/2018		D	625 (2)	(3) 02/08/2022	Common Stock	625 (2)
Stock Option (Right to Buy)	\$ 31.92	11/12/2018		D	1,458 (2)	(3) 02/08/2022	Common Stock	1,458 (2)
Stock Option (Right to Buy)	\$ 111.84	11/12/2018		D	416 (2)	(3) 06/09/2023	Common Stock	416 (2)

Edgar Filing: BALTIMORE DAVID - Form 4

Stock Option (Right to Buy)	\$ 111.84	11/12/2018	D	1,458 (2)	(3)	06/09/2023	Common Stock	1,458 (2)
Stock Option (Right to Buy)	\$ 74.64	11/12/2018	D	1,458 (2)	(3)	05/21/2024	Common Stock	1,458 (2)
Stock Option (Right to Buy)	\$ 74.64	11/12/2018	D	416 (2)	(3)	05/21/2024	Common Stock	416 (2)
Stock Option (Right to Buy)	\$ 120.24	11/12/2018	D	1,458 (2)	(3)	06/08/2025	Common Stock	1,458 (2)
Stock Option (Right to Buy)	\$ 74.4	11/12/2018	D	3,051 (2)	(3)	05/31/2026	Common Stock	3,051 (2)
Stock Option (Right to Buy)	\$ 17.4	11/12/2018	D	2,500 (2)	(3)	05/30/2027	Common Stock	2,500 (2)
Stock Option (Right to Buy)	\$ 8.52	11/12/2018	D	6,250 (2)	(5)	05/15/2028	Common Stock	6,250 (2)
Stock Option (Right to Buy)	\$ 8.76	11/12/2018	D	4,583 (2)	(6)	05/31/2028	Common Stock	4,583 (2)

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BALTIMORE DAVID C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121	X			

## Signatures

Christopher Aker, Attorney  
in Fact

11/13/2018

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I. The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date.
  - (2) Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018.
  - (3) The shares subject to the cancelled option were fully vested.
  - (4) On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I.
  - (5) The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant.
  - (6) The cancelled option provided for vesting in twelve equally monthly installments, such that the option would be fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occurred first.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.